# **Complete Summary**

#### **GUIDELINE TITLE**

Contact precautions in hospitals. In: Prevention and control of healthcareassociated infections in Massachusetts.

## **BIBLIOGRAPHIC SOURCE(S)**

Contact precautions in hospitals. In: Betsy Lehman Center for Patient Safety and Medical Error Reduction, JSI Research and Training Institute, Inc. Prevention and control of healthcare-associated infections in Massachusetts. Part 1: final recommendations of the Expert Panel. Boston (MA): Massachusetts Department of Public Health; 2008 Jan 31. p. 50-3.

## **GUIDELINE STATUS**

This is the current release of the guideline.

## **COMPLETE SUMMARY CONTENT**

**SCOPE** 

METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

## **SCOPE**

## **DISEASE/CONDITION(S)**

Healthcare-associated infections

#### **GUIDELINE CATEGORY**

Prevention

## **CLINICAL SPECIALTY**

Infectious Diseases Internal Medicine Preventive Medicine Surgery

#### **INTENDED USERS**

Advanced Practice Nurses Hospitals Nurses Physician Assistants Physicians

## **GUIDELINE OBJECTIVE(S)**

- To provide evidence-based recommendations for a statewide infection control and prevention program to improve health outcomes by reducing the risk of acquiring and transmitting healthcare-associated infections
- To provide recommendations for contact precautions in hospitals

#### **TARGET POPULATION**

Hospital patients with or at risk of healthcare-associated infections

## INTERVENTIONS AND PRACTICES CONSIDERED

- 1. Use of standard and transmission-based precautions
- 2. Use of contact precautions including
  - Appropriate patient placement
  - Use of personal protective equipment (PPE) such as gloves and gowns
  - Appropriate patient transport
  - Care of equipment, instruments, and devices
  - Environmental measures

## **MAJOR OUTCOMES CONSIDERED**

Incidence of healthcare-associated infections

## **METHODOLOGY**

## METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources) Hand-searches of Published Literature (Secondary Sources) Searches of Electronic Databases

## DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The Expert Panel was divided into six task groups. In order to generate sound, evidence-based recommendations, a comprehensive reference library was created for each task group comprising articles, publications, and other materials relevant to their work. An expert in library science, aided by a JSI Research and Training

Institute, Inc. (JSI) staff member with experience in literature review, conducted literature searches, selected articles for inclusion, and managed and organized the task group libraries. For the purpose of the project, JSI gathered an extensive body of literature (over 2000 published articles). Starting with the reference library of a local healthcare associated infections (HAI) expert, it was supplemented and updated to include the most current articles and expanded on recommendations made by Expert Panel and task group members. Figure 1 in the original guideline document summarizes the literature review process.

Literature searches were conducted in PubMed using applicable Medical Subject Headings (MeSH) and key words. Refer to Figure 2 in the original guideline document for information on literature search methodology.

## NUMBER OF SOURCE DOCUMENTS

Not stated

# METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

#### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

## **Level of Evidence Ranking**

**Level I**: Strong evidence from at least one well-designed randomized controlled trial

**Level II**: Evidence from well-designed non-randomized trials; cohort or case-controlled analytic studies (preferably from >1 center); multiple time-series studies

**Level III**: Well-designed descriptive studies from more than one center or research group

**Level IV**: Opinions of authorities (e.g., guidelines), clinical evidence; reports of expert committees

**Level V**: No quality studies found and no clear guidance from expert committees, authorities or other sources

## METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

## **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

To aid the task groups and Expert Panel in their decisions, JSI Research and Training Institute, Inc. (JSI) generated qualitative summaries and reviews of

relevant literature, outlining the current "state of the science" on task group-indicated topics of debate. All selected studies were critically assessed for internal validity or methodological rigor and only those with high quality of evidence grades were considered in generating evidence-based recommendations.

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus (Consensus Development Conference) Expert Consensus (Delphi)

# DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

The 2006 Health Care Reform Law directed the Massachusetts Department of Public Health (MDPH) to establish a comprehensive state wide infection prevention and control program. To direct this new effort, a healthcare-associated infection (HAI) Expert Panel was convened in November 2006 under the auspices of the Betsy Lehman Center for Patient Safety and Medical Error Reduction and MDPH. This multidisciplinary panel of experts included infectious disease specialists, epidemiologists, infection control and hospital quality professionals, consumers, professional organizations, and hospital executives and clinical leaders. Research, coordination and facilitation of the work of the Expert Panel and the associated Task Groups was provided by JSI Research and Training Institute, a public health research and consulting firm located in Boston.

The mission of the Expert Panel was to provide guidance on all aspects of a statewide infection control and prevention program, review the key elements of such a program, and submit their completed recommendations to the Betsy Lehman Center and the Massachusetts Department of Public Health by January 31, 2008.

The Expert Panel held twelve monthly meetings beginning on November 30, 2006. Due to the multi-faceted nature of the Panel's charge, six Task Groups were formed in order to focus the efforts of Panel members on their respective areas of expertise.

- 1. Bloodstream and Surgical Site Infections (BSI, SSI)--Prevention, Surveillance, and Reporting
- 2. Optimal Infection Control Program Components
- 3. Ventilator-Associated Pneumonia (VAP)--Prevention, Surveillance, and Reporting
- 4. Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Other Selected Pathogens--Prevention, Surveillance, and Reporting
- 5. Public Reporting and Communication
- 6. Pediatric Affinity Group--Prevention, Surveillance, and Reporting

Panel members were asked to join at least one group, aligning with their expertise and interest. Additionally, group membership was supplemented with experts and stakeholders from outside the Expert Panel. Each task group was led by an Expert Panel member (Task Group Leader) who facilitated the calls and assisted in the literature review process. Task groups held one-hour-long conference calls every three weeks. A JSI coordinator supported each task group by reviewing and

summarizing the literature and aiding in drafting recommendations. Coordinators were also responsible for all administrative work including minute taking, distribution of materials, and communication between the Expert Panel and task groups.

Due to time and capacity limitations, catheter-associated urinary tract infections (CAUTI) were not a specific task group topic. However, the product of a parallel process of evidence review and guideline updating, by experts representing the Infectious Disease Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA), was graciously made available to our project. An ad hoc committee of Expert Panel members and outside experts studied and endorsed these prevention guidelines and they have been incorporated into this final report.

Expert Panel recommendations, in addition to being scientifically sound, needed to take into account the current practices of infection control programs in Massachusetts. For this purpose, JSI surveyed infection control program directors across the Commonwealth in the areas of prevention, surveillance, reporting, and education relating to HAIs. The comprehensive survey questionnaire was developed using a review of current literature, expert reports, and existing surveys. After receiving input and approval from the Expert Panel and the Harvard Pilgrim Health Care Institutional Review Board, the survey was piloted in six hospitals. Once final revisions were made, the survey was mailed to the infection control program of all 71 acute care (non-Veterans Administration) hospitals in Massachusetts. A follow-up phone interview was also conducted to solicit more qualitative information and clarify any answers on the written survey. The completed survey responses were analyzed and results were distributed to project members to aid in their decision-making.

Taking into consideration both the results of the survey and the evidence, task groups drafted recommendations in the areas of HAI prevention and reporting. When voting, either during meetings or electronically, task group members had the opportunity to make comments and suggest additional changes. JSI then tallied the task group votes, reviewed comments, and brought back any major points of contention to the task group.

#### RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

## **Strength of Recommendation Ranking**

**Category A:** Strongly recommended

**Category B**: Recommended for implementation

**Category C**: Consider for implementation

**Category D**: Recommended against implementation

Category UI: Unresolved issue

**No recommendation**: Unresolved issue. Practices for which insufficient evidence or no consensus regarding efficacy exists.

#### COST ANALYSIS

The annual economic burden of healthcare-associated infections (HAI) in Massachusetts ranges from approximately \$200 million to well over \$400 million. While it is difficult to determine a precise estimate, it is clear that these infections are costly. Mandatory reporting of institutional-level HAI is a potential tool for improvement of quality of care and a method to be used by consumers, insurers, or providers to make decisions regarding where to seek or fund healthcare. If HAI are reduced with mandatory reporting, societal cost-savings should be anticipated. However, the effect of mandatory reporting on HAI rates is yet unknown. Additionally, increased costs to the hospitals and the Department of Public Health (DPH) should be anticipated. The methods used in this report should be beneficial to other state DPH. With limited resources and the potential benefits of public reporting yet to be established, there is a need to carefully balance the additional burden of reporting with current prevention efforts in order to obtain the optimum outcome, less infections.

Refer to Prevention and Control of Healthcare-Associated Infections in Massachusetts, Part 2: Findings from Complementary Research Activities (see the "Availability of Companion Documents" field) for more information on costanalysis.

#### METHOD OF GUIDELINE VALIDATION

Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Once recommendations were approved by the task group members, they were presented to the Expert Panel for consideration and any necessary final revisions.

## RECOMMENDATIONS

## **MAJOR RECOMMENDATIONS**

Note from the Massachusetts Department of Public Health (MDPH) and the National Guideline Clearinghouse (NGC): Prevention and Control of Healthcare-Associated Infections in Massachusetts guideline has been divided into individual summaries. In addition to the current summary, the following are available:

- Hand hygiene recommendations
- Standard precautions in hospitals
- Environmental measures for the prevention and management of multi-drug resistant organisms
- Prevention of ventilator-associated pneumonia
- Prevention of surgical site infections
- Prevention of bloodstream infections

Prevention of catheter-associated urinary tract infections

Level of evidence ranking (I - V) and strength of recommendation ranking (A - D, U) Unresolved issue [UI], No recommendation) definitions are presented at the end of "Major Recommendations" field.

## **General Principles**

- In addition to Standard Precautions, use transmission-based precautions for patients with documented or suspected infection or colonization with highly transmissible or epidemiologically-important pathogens for which additional precautions are needed to prevent transmission (see Attachment B in the original guideline document for type and duration of precautions recommended for multi-drug resistant organisms [MDROs], infection or colonization). A-IV\*
- 2. Extend duration of transmission-based precautions, (e.g., droplet, contact) for immunosuppressed patients with viral infections due to prolonged shedding of viral agents that may be transmitted to others. **A-IV**\*

#### **Contact Precautions**

3. Use Contact Precautions as recommended in Appendix A (2007 HICPAC Isolation Precaution Guidelines pages 93-113) for patients with known or suspected infections or evidence of syndromes that represent an increased risk for contact transmission. For specific recommendations for use of Contact Precautions for colonization or infection with MDROs, go to the MDRO guideline (Management of Multidrug-Resistant Organisms in Healthcare Settings Guideline). A-IV (Siegel et al., 2006)

## Patient Placement

4. In acute care hospitals, place patients who require Contact Precautions in a single-patient room when available. **B-IV**\*

When single-patient rooms are in short supply, apply the following principles for making decisions on patient placement:

- A. Prioritize patients with conditions that may facilitate transmission (e.g., uncontained drainage, stool incontinence) for single-patient room placement. **B-IV**\*
- B. Place together in the same room (cohort) patients who are infected or colonized with the same pathogen and are suitable roommates. **B-IV**\*
- C. If it becomes necessary to place a patient who requires contact precautions in a room with a patient who is not infected or colonized with the same infectious agent:
  - Avoid placing patients on contact precautions in the same room with patients who have conditions that may increase the risk of adverse outcome from infection or that may facilitate transmission (e.g., those who are immunocompromised, have open wounds, or have anticipated prolonged lengths of stay).
     B-IV\*

- Ensure that patients are physically separated (i.e., >3 feet apart) from each other. Draw the privacy curtain between beds to minimize opportunities for direct contact.) **B-IV**\*
- Change protective attire and perform hand hygiene between contact with patients in the same room, regardless of whether one or both patients are on contact precautions. B-IV\*
- D. In ambulatory settings, place patients who require contact precautions in an examination room or cubicle as soon as possible. **B-IV**\*

Use of Personal Protective Equipment (PPE)

## Gloves

 Wear gloves whenever touching the patient's intact skin or surfaces and articles in close proximity to the patient (e.g., medical equipment, bed rails).
 Don gloves upon entry into the room or cubicle. B-IV\*

## Gowns

- 6. A. Wear a gown whenever anticipating that clothing will have direct contact with the patient or potentially contaminated environmental surfaces or equipment in close proximity to the patient. Don gown upon entry into the room or cubicle. Remove gown and observe hand hygiene before leaving the patient-care environment. **B-IV**\*
- 7. B. After gown removal, ensure that clothing and skin do not contact potentially contaminated environmental surfaces that could result in possible transfer of microorganism to other patients or environmental surfaces. **B-IV**\*

## Patient Transport

- A. In acute care hospitals and long-term care and other residential settings, limit transport and movement of patients outside of the room to medicallynecessary purposes. B-IV\*
  - B. When transport or movement in any healthcare setting is necessary, ensure that infected or colonized areas of the patient's body are contained and covered.  $\textbf{\textit{B-IV}}^*$
  - C. Remove and dispose of contaminated PPE and perform hand hygiene prior to transporting patients on contact precautions.  $\textit{B-IV}^*$
  - D. Don clean PPE to handle the patient at the transport destination. **B-IV\***

## Patient-Care Equipment and Instruments/Devices

- 8. A. Handle patient-care equipment and instruments/devices according to standard precautions. **B-IV**\*
  - B. In acute care hospitals and long-term care and other residential settings, use disposable noncritical patient-care equipment (e.g., blood pressure cuffs) or implement patient-dedicated use of such equipment. If common use of equipment for multiple patients is unavoidable, clean and disinfect such equipment before use on another patient. **B-IV**\*
  - C. In ambulatory settings, place contaminated reusable noncritical patient-

care equipment in a plastic bag for transport to a soiled utility area for reprocessing. **B-IV**\*

#### Environmental Measures

9. Ensure that rooms of patients on contact precautions are prioritized for frequent cleaning and disinfection (e.g., at least daily) with a focus on frequently-touched surfaces (e.g., bed rails, overbed table, bedside commode, lavatory surfaces in patient bathrooms, doorknobs) and equipment in the immediate vicinity of the patient. **B-IV**\*

#### Discontinue Contact Precautions

10. No recommendation can be made as to when to discontinue contact precautions for both multi-drug resistant organisms (MDROs) (see Attachment B in the original guideline document) and Clostridium difficile. B-IV\*

#### **Definitions:**

## **Level of Evidence Ranking**

**Level I**: Strong evidence from at least one well-designed randomized controlled trial

**Level II**: Evidence from well-designed non-randomized trials; cohort or case-controlled analytic studies (preferably from >1 center); multiple time-series studies

**Level III**: Well-designed descriptive studies from more than one center or research group

**Level IV**: Opinions of authorities (e.g., guidelines), clinical evidence; reports of expert committees

**Level V**: No quality studies found and no clear guidance from expert committees, authorities or other sources

## Strength of Recommendation Ranking

Category A: Strongly recommended

**Category B**: Recommended for implementation

**Category C**: Consider for implementation

**Category D**: Recommended against implementation

<sup>\*</sup>Identifies evidence from the Centers for Disease Control and Prevention (CDC)'s updated guidelines without repeating the detailed literature review process.

Category UI: Unresolved issue

**No recommendation**: Unresolved issue. Practices for which insufficient evidence or no consensus regarding efficacy exists.

## **CLINICAL ALGORITHM(S)**

None provided

# **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

## REFERENCES SUPPORTING THE RECOMMENDATIONS

References open in a new window

## TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

## BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### **POTENTIAL BENEFITS**

Evidence-based best practice guidelines and interventions for prevention of healthcare-associated infection will promote patient and healthcare worker safety and improve health outcomes by reducing the risk of acquiring and transmitting healthcare associated infections.

## **POTENTIAL HARMS**

Not stated

## **IMPLEMENTATION OF THE GUIDELINE**

#### **DESCRIPTION OF IMPLEMENTATION STRATEGY**

The final recommendations contained in *Prevention and Control of Healthcare-Associated Infections in Massachusetts* were adopted by the Betsy Lehman Center for Patient Safety and Medical Error Reduction (BLC) and the Massachusetts Department of Public Health (MDPH). MDPH incorporated the recommendations into the reporting requirements, and developed an assessment tool for surveyors to use to evaluate the implementation of best practices.

## **IMPLEMENTATION TOOLS**

Staff Training/Competency Material

For information about <u>availability</u>, see the "Availability of Companion Documents" and "Patient Resources" fields below.

# INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

## **IOM CARE NEED**

Staying Healthy

#### **IOM DOMAIN**

Effectiveness Safety

## **IDENTIFYING INFORMATION AND AVAILABILITY**

## **BIBLIOGRAPHIC SOURCE(S)**

Contact precautions in hospitals. In: Betsy Lehman Center for Patient Safety and Medical Error Reduction, JSI Research and Training Institute, Inc. Prevention and control of healthcare-associated infections in Massachusetts. Part 1: final recommendations of the Expert Panel. Boston (MA): Massachusetts Department of Public Health; 2008 Jan 31. p. 50-3.

#### **ADAPTATION**

The guideline was adapted from: Siegel, J. D., E. Rhinehart, et al. (2007). 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 35(10 Suppl 2): S65-164.

#### **DATE RELEASED**

2008 Jan 31

# **GUIDELINE DEVELOPER(S)**

Betsy Lehman Center for Patient Safety and Medical Error Reduction - State/Local Government Agency [U.S.]

Massachusetts Department of Public Health - State/Local Government Agency [U.S.]

## **SOURCE(S) OF FUNDING**

Massachusetts Department of Public Health

## **GUIDELINE COMMITTEE**

Massachusetts Healthcare-Associated Infections Expert Panel

## **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

Panel Members: Richard T. Ellison III, MD (Chair) Hospital Epidemiologist, Professor of Medicine, Molecular Genetics and Microbiology, University of Massachusetts Memorial Medical Center; Mary Ellen Scales, RN, MSN, CIC (Vice-Chair) Manager, Infection Control, Baystate Medical Center; Mary Alexander, RN, Chief Executive Officer, Infusion Nurse's Society; Eric Alper, MD, Internal Medicine, University of Massachusetts Memorial Medical Center; Evie Bain, RN, Occupational Health & Safety, Massachusetts Nurses Association; Anne Baras, RN, Surgical Technology Department Chair, North Shore Community College; Karen Boudreau, MD, Medical Director, Healthcare Quality Improvement, Blue Cross Blue Shield of MA; Ann Marie Bourque, NP, President, New England Chapter of the National Conference of Gerontological Nurse Practitioners; Lou Ann Bruno-Murtha, MD, Medical Director, Infection Control Division Chief, Cambridge Health Alliance; Wanda Carey, RN, BSN, CIC, Manager, Infection Control, Caritas Norwood Hospital; Philip Carling, MD, Director, Infectious Diseases and Hospital Epidemiology, Caritas Carney Hospital; Donald Craven, MD, Chair, Infectious Disease, Lahey Clinic; Jane Foley, RN, Director of Operations, Nursing, Beth Israel-Deaconess Medical Center; Denise Graham, Sr. Director Public Policy, Association for Professionals in Infection Control and Epidemiology: Paula Griswold, MS, Executive Director, Massachusetts Coalition for the Prevention of Medical Errors; David Hooper, MD, Internal Medicine/ID, Massachusetts General Hospital; Linda Kenney, President, Executive Director, Medically Induced Trauma Support Services; Jim Liljestrand, MD, Medical Director, Quality Improvement, MassPro: Michael Mitchell, MD, Director, Microbiology Services, University of Massachusetts Memorial Medical Center; Sharon-Lise Normand, PhD, Professor of Biostatistics, Harvard Medical School; Richard Olans, MD, Director, Infectious Disease, Hallmark Health Hospitals; Gail Potter-Bynoe, BS, CIC, Manager, Infection Control, Children's Hospital Boston; Selwyn Rogers, MD, Division Chief, Trauma, Burns, and Surgical Critical Care, Director, Center for Surgery and Public Health, Assistant Professor of Surgery, Brigham and Women's Hospital; Jeannie Sanborn, RN, MS, CIC, Infection Control Professional Heywood Hospital; Thomas Sandora, MD, Pediatric ID, Children's Hospital Boston; Kenneth Sands, MD, Senior Vice President, Health Care Quality, Beth Israel-Deaconess Medical Center; Christine Schuster, RN, CEO and President, Emerson Hospital; David Smith, MHSA, Senior Director, Health Data Analysis & Research, Massachusetts Hospital Association; Carol Sulis, MD, Hospital Epidemiologist, Associate Professor of Medicine, Boston Medical Center; Thomas Sullivan, MD, Cardiologist in Private Practice, Women's Health Center Cardiology (Danvers)

## FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

## **GUIDELINE STATUS**

This is the current release of the guideline.

#### **GUIDELINE AVAILABILITY**

Electronic copies: Available in Portable Document Format (PDF) from the Massachusetts Department of Public Health Web site.

## **AVAILABILITY OF COMPANION DOCUMENTS**

The following are available:

- Betsy Lehman Center for Patient Safety and Medical Error Reduction, JSI
  Research and Training Institute, Inc. Prevention and control of healthcareassociated infections in Massachusetts. Part 2: findings from complementary
  research activities. Boston (MA): Massachusetts Department of Public Health;
  2008 Jan 31. 131 p. Available in Portable Document Format (PDF) from the
  Massachusetts Department of Public Health Web site.
- Handwashing education materials for health care professionals. Available from the Massachusetts Department of Public Health Web site.

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This NGC summary was completed by ECRI Institute on October 3, 2008. The information was verified by the guideline developer on December 22, 2009.

## **COPYRIGHT STATEMENT**

No copyright restrictions apply.

## **DISCLAIMER**

## **NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href="http://www.quideline.gov/about/inclusion.aspx">http://www.quideline.gov/about/inclusion.aspx</a>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

© 1998-2009 National Guideline Clearinghouse

Date Modified: 2/9/2009

